New research reveals that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight far faster than those who halt traditional diet and exercise programs.
Published data in a major medical journal points out that while obese people frequently drop substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such drugs should be aware of the potential of quick rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about 18 months.
Weighing Treatments
The study, which examined dozens of studies involving thousands of participants, compared the results of the injectable medications with conventional dieting.
Researchers point out that people who lose weight through diet and exercise generally see a slower weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Experts believe the way of the injections accounts for the amplified weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, considering the likelihood of weight regain, the treatment is often long-term.
This opinion is reinforced by drug manufacturers, who note that the findings "emphasize the long-term nature of obesity," akin to managing conditions like high blood pressure.
User Accounts
Individuals who have discontinued the jabs report a intense resurgence of hunger.
"I experienced a trigger that goes on and you become ravenous," recalled one woman.
The struggle is compounded if users have not adopted permanent lifestyle or habit modifications during therapy.
Growing Use
Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is higher among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits hinges on ongoing behavioural management.
